A groundbreaking clinical trial has commenced, testing the world's first mRNA lung cancer vaccine, marking a significant milestone in cancer treatment.
The vaccine, named BNT116 and developed by BioNTech, is specifically designed to combat non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer. Utilizing mRNA technology, the vaccine works by instructing the immune system to identify and destroy cancer cells, with the potential to prevent the disease from recurring.
Janusz Racz, a 67-year-old scientist from London, became the first patient in the UK to receive the vaccine. Racz expressed hope that this innovative treatment will not only benefit him personally but also pave the way for broader adoption of what could be a life-saving therapy for many others.
.jpeg)
No comments:
Post a Comment